Multiplex assays reveal anti‐ EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma
International Journal of Cancer · 2024
DOI: 10.1002/ijc.35061 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Lin Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carc…. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Antibodies, Viral, Nasopharyngeal Carcinoma, Herpesvirus 4, Human. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Science Fund for Excellent Young Scholars, Basic and Applied Basic Research Foundation of Guangdong Province, National Key Research and Development Program of China.
Abstract (Originalsprache)
Epstein–Barr virus (EBV) is detected in nearly 100% of nonkeratinizing nasopharyngeal carcinoma (NPC) and EBV‐based biomarkers are used for NPC screening in endemic regions. Immunoglobulin A (IgA) against EBV nuclear antigen 1 (EBNA1) and viral capsid antigen (VCA), and recently identified anti‐BNLF2b antibodies have been shown to be the most effective screening tool; however, the screening efficacy still needs to be improved. This study developed a multiplex serological assay by testing IgA and immunoglobulin G (IgG) antibodies against representative EBV antigens that are highly transcribed in NPC and/or function crucially in viral reactivation, including BALFs, BNLF2a/b, LF1, LF2, and Zta (BZLF1). Among them, BNLF2b‐IgG had the best performance distinguishing NPC patients from controls (area under the curve: 0.951, 95% confidence interval [CI]: 0.913–0.990). Antibodies to lytic antigens BALF2 and VCA were significantly higher in advanced‐stage than in early‐stage tumors; in contrast, antibodies to latent protein EBNA1 and early lytic antigen BNLF2b were not correlated with tumor progression. Accordingly, a novel strategy combining EBNA1‐IgA and BNLF2b‐IgG was proposed and validated improving the integrated discrimination by 15.8% (95% CI: 9.8%–21.7%, p < .0001) compared with the two‐antibody method. Furthermore, we found EBV antibody profile in patients was more complicated compared with that in healthy carriers, in which stronger correlations between antibodies against different phases of antigens were observed. Overall, our serological assay indicated that aberrant latent infection of EBV in nasopharyngeal epithelial cells was probably a key step in NPC initiation, while more lytic protein expression might be involved in NPC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Gua…
- School of Public Health, Sun Yat-sen University, Guangzhou, China.
- Guangdong Key Laboratory of Human Evolution and Archaeometry, Department of Anthropology, School of Sociology and Anthropology, Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Tong-Min Wang, Wei-Hua Jia, Lin Feng
Förderung
- National Science Fund for Excellent Young Scholars
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Key Research and Development Program of China
- Sun Yat-sen University Interdisciplinary Cultivation Funding Project
- National Natural Science Foundation of China
Zitieren
APA
Ma, L., Wang, T. M., He, Y. Q., Liao, Y., Yan, X., Yang, D. W., Wang, R. H., Li, F. J., Jia, W. H., & Feng, L. (2024). Multiplex assays reveal anti‐ EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.35061
Vancouver
Ma L, Wang TM, He YQ, Liao Y, Yan X, Yang DW, et al. Multiplex assays reveal anti‐ EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma. International Journal of Cancer. 2024. doi:10.1002/ijc.35061
BibTeX
@article{Ma2024,
author = {Ma, Lin and Wang, Tong-Min and He, Yong-Qiao and Liao, Ying and Yan, Xiao and Yang, Da-Wei and Wang, Rui-Hua and Li, Fa-Jun and Jia, Wei-Hua and Feng, Lin},
title = {Multiplex assays reveal anti‐ EBV antibody profile and its implication in detection and diagnosis of nasopharyngeal carcinoma},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.35061}
}
EUVIMED